Stockreport

Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

RA PHARMACEUTICALS  (RARX) 
Last ra pharmaceuticals earnings: 11/7 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: rapharma.com/news-investors
PDF - Dosing Complete, Primary Endpoint Met in Eculizumab Naïve Cohort (p=0.002 for LDH reduction)- Switch Cohort: Interim Data Demonstrate Successful Switch [Read more]